226 related articles for article (PubMed ID: 33093219)
1. Activin A Promotes Regulatory T-cell-Mediated Immunosuppression in Irradiated Breast Cancer.
De Martino M; Daviaud C; Diamond JM; Kraynak J; Alard A; Formenti SC; Miller LD; Demaria S; Vanpouille-Box C
Cancer Immunol Res; 2021 Jan; 9(1):89-102. PubMed ID: 33093219
[TBL] [Abstract][Full Text] [Related]
2. Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.
Budhu S; Schaer DA; Li Y; Toledo-Crow R; Panageas K; Yang X; Zhong H; Houghton AN; Silverstein SC; Merghoub T; Wolchok JD
Sci Signal; 2017 Aug; 10(494):. PubMed ID: 28851824
[TBL] [Abstract][Full Text] [Related]
3. TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity.
Vanpouille-Box C; Diamond JM; Pilones KA; Zavadil J; Babb JS; Formenti SC; Barcellos-Hoff MH; Demaria S
Cancer Res; 2015 Jun; 75(11):2232-42. PubMed ID: 25858148
[TBL] [Abstract][Full Text] [Related]
4. YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity.
Ni X; Tao J; Barbi J; Chen Q; Park BV; Li Z; Zhang N; Lebid A; Ramaswamy A; Wei P; Zheng Y; Zhang X; Wu X; Vignali P; Yang CP; Li H; Pardoll D; Lu L; Pan D; Pan F
Cancer Discov; 2018 Aug; 8(8):1026-1043. PubMed ID: 29907586
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant immune checkpoint blockade triggers persistent and systemic T
Blomberg OS; Kos K; Spagnuolo L; Isaeva OI; Garner H; Wellenstein MD; Bakker N; Duits DEM; Kersten K; Klarenbeek S; Hau CS; Kaldenbach D; Raeven EAM; Vrijland K; Kok M; de Visser KE
Oncoimmunology; 2023; 12(1):2201147. PubMed ID: 37089449
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.
Muroyama Y; Nirschl TR; Kochel CM; Lopez-Bujanda Z; Theodros D; Mao W; Carrera-Haro MA; Ghasemzadeh A; Marciscano AE; Velarde E; Tam AJ; Thoburn CJ; Uddin M; Meeker AK; Anders RA; Pardoll DM; Drake CG
Cancer Immunol Res; 2017 Nov; 5(11):992-1004. PubMed ID: 28970196
[TBL] [Abstract][Full Text] [Related]
7. Engineered Hybrid Treg-Targeted Nanosomes Restrain Lung Immunosuppression by Inducing Intratumoral CD8
Domvri K; Petanidis S; Zarogoulidis P; Anestakis D; Charalampidis C; Tsavlis D; Huang H; Freitag L; Hohenforst-Schmidt W; Matthaios D; Katopodi T; Porpodis K
Int J Nanomedicine; 2022; 17():4449-4468. PubMed ID: 36172007
[TBL] [Abstract][Full Text] [Related]
8. Activin A backs-up TGF-ß to promote regulatory T cells.
De Martino M; Daviaud C; Vanpouille-Box C
Oncoimmunology; 2021 Feb; 10(1):1883288. PubMed ID: 33628624
[TBL] [Abstract][Full Text] [Related]
9. Targeting the activin receptor 1C on CD4+ T cells for cancer immunotherapy.
Zheng Y; Lebid A; Chung L; Fu J; Wang X; Otrocol A; Zarif JC; Yu H; Llosa NJ; Pardoll DM
Oncoimmunology; 2024; 13(1):2297503. PubMed ID: 38235319
[TBL] [Abstract][Full Text] [Related]
10. Foxp3
Kohno M; Murakami J; Wu L; Chan ML; Yun Z; Cho BCJ; de Perrot M
J Immunol; 2020 Nov; 205(9):2519-2531. PubMed ID: 32948683
[TBL] [Abstract][Full Text] [Related]
11. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
[TBL] [Abstract][Full Text] [Related]
12. Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma.
Pinjusic K; Dubey OA; Egorova O; Nassiri S; Meylan E; Faget J; Constam DB
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580932
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer.
Joffroy CM; Buck MB; Stope MB; Popp SL; Pfizenmaier K; Knabbe C
Cancer Res; 2010 Feb; 70(4):1314-22. PubMed ID: 20145137
[TBL] [Abstract][Full Text] [Related]
14. MEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieu.
Hossain DM; Panda AK; Chakrabarty S; Bhattacharjee P; Kajal K; Mohanty S; Sarkar I; Sarkar DK; Kar SK; Sa G
Immunology; 2015 Apr; 144(4):561-73. PubMed ID: 25284464
[TBL] [Abstract][Full Text] [Related]
15. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
[TBL] [Abstract][Full Text] [Related]
16. Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors.
Castiglioni A; Yang Y; Williams K; Gogineni A; Lane RS; Wang AW; Shyer JA; Zhang Z; Mittman S; Gutierrez A; Astarita JL; Thai M; Hung J; Yang YA; Pourmohamad T; Himmels P; De Simone M; Elstrott J; Capietto AH; Cubas R; Modrusan Z; Sandoval W; Ziai J; Gould SE; Fu W; Wang Y; Koerber JT; Sanjabi S; Mellman I; Turley SJ; Müller S
Nat Commun; 2023 Aug; 14(1):4703. PubMed ID: 37543621
[TBL] [Abstract][Full Text] [Related]
17. The role of activin in mammary gland development and oncogenesis.
Dunphy KA; Schneyer AL; Hagen MJ; Jerry DJ
J Mammary Gland Biol Neoplasia; 2011 Jun; 16(2):117-26. PubMed ID: 21475961
[TBL] [Abstract][Full Text] [Related]
18. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
[No Abstract] [Full Text] [Related]
19. The effects of activin A on the migration of human breast cancer cells and neutrophils and their migratory interaction.
Xie D; Liu Z; Wu J; Feng W; Yang K; Deng J; Tian G; Santos S; Cui X; Lin F
Exp Cell Res; 2017 Aug; 357(1):107-115. PubMed ID: 28479070
[TBL] [Abstract][Full Text] [Related]
20. Role of activin A in the induction of Foxp3+ and Foxp3- CD4+ regulatory T cells.
Huber S; Schramm C
Crit Rev Immunol; 2011; 31(1):53-60. PubMed ID: 21395511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]